QIAGEN has launched ScreenGel software for convenient DNA fragment and RNA analysis with the QIAxcel multicapillary gel electrophoresis systems. The software combines flexibility for researchers with standardized and reproducible operations in the lab.
Molecular Profiles, a leading pharmaceutical development service provider, announces the continued expansion of its manufacturing capabilities with the recent purchase of the Xcelodose 120S system.
Thermo Fisher Scientific Inc. announced the initial findings of stroke research conducted by its Biomarker Research Initiatives in Mass Spectrometry Center in collaboration with Massachusetts General Hospital, Harvard University.
Using a relatively simple cell-based fluorescent assay they developed, scientists have identified a means by which fluoxetine, the active ingredient in Prozac, suppresses the activity of the TREK1 potassium channel.
After analyzing hundreds of proteins produced by the DNA of tumor cells, researchers have identified one protein that may be central to a new treatment for the often-fatal childhood cancer neuroblastoma.
Rib-X Pharmaceuticals, Inc. initiated a Phase 2b clinical trial to evaluate delafloxacin, linezolid, and vancomycin for the treatment of acute bacterial skin and skin structure infections, including infections caused by methicillin-resistant Staphylococcus aureus.
Genentech announced that OCEANS, a Phase 3 study evaluating Avastin in combination with chemotherapy followed by continued use of Avastin alone until disease progression in women with recurrent, platinum-sensitive ovarian cancer, met its primary endpoint.
Purdue University's Bindley Bioscience Center has installed a high-end imaging instrument to advance research in the areas of cancer, neuroscience, and cardiovascular and musculoskeletal diseases.
Gilead Sciences Inc. said that Natco Pharma Ltd. is challenging a patent on the flu drug Tamiflu. Tamiflu was developed by Gilead, which receives royalties on the drug's sale from Roche Holding AG.
In 2010, the National Institutes of Health was able to fund fewer than 25 percent of the research grant applications submitted to its 27 institutes and centers. In 2011, the National Health Council is giving unfunded NIH applications the potential for a new lease on life.
King Pharmaceuticals Inc. said it plans to voluntarily delist its stock from the New York Stock Exchange as it completes its sale to Pfizer Inc. The company said its stock will be listed through Feb. 28.
Indiana University has announced a major commitment to research in one of health care's most promising fields with the creation of the Indiana Institute for Personalized Medicine.
Clinical-stage drugmaker Pharmasset Inc. reported a wider fiscal first-quarter loss Monday on higher research and development costs. The company lost $23.5 million, compared with a loss of $13.9 million the same quarter a year prior.
GlaxoSmithKline PLC said it has updated the labeling of its diabetes pill Avandia to include safety restrictions ordered by federal health authorities because of the drug's links to heart attack.
Beckman Coulter, Inc. announced that it has entered into a definitive merger agreement under which Danaher will acquire all of Beckman Coulter's outstanding common stock for $83.50 per share in cash.